Press Releases
This section of Viatris.com contains information that may not be suitable for use in all countries due to varied regulatory requirements, data protection requirements and practices or medical practices, and distinctions among product approval and commercial availability. The information contained in each news release or statement posted on this page is presented as of the date it was issued. The company undertakes no obligation to update the information for changes or subsequent events after the date it was originally issued.
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Jan 3, 2023
- Dec 29, 2022
- Dec 23, 2022
- Dec 14, 2022
- Dec 14, 2022
- Nov 29, 2022
- Nov 18, 2022
- Nov 10, 2022
- Nov 7, 2022
- Nov 7, 2022
- Oct 25, 2022
- Oct 24, 2022
- Oct 11, 2022
- Sep 6, 2022
- Aug 8, 2022
- Jul 5, 2022
- Jul 1, 2022
- May 20, 2022
- May 19, 2022
- May 16, 2022
- May 9, 2022
- Apr 12, 2022
- Apr 8, 2022
- Mar 30, 2022
- Mar 17, 2022
- Mar 16, 2022
- Mar 1, 2022
- Feb 28, 2022
- Feb 4, 2022
- Feb 3, 2022Approval Reinforces Viatris' Steadfast Commitment to Breaking Down Barriers and Expanding Access to Complex Generic Products
- Jan 18, 2022
- Jan 6, 2022
- Dec 29, 2021Decisions reaffirm Viatris' ability to provide patient access to interchangeable Semglee®
- Dec 17, 2021
- Dec 6, 2021
- Dec 1, 2021
- Nov 18, 2021
- Nov 16, 2021Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
- Nov 11, 2021The multi-year impact investment will rebuild homes for at least 50 veterans
- Nov 8, 2021Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share
- Oct 20, 2021Upcoming launch of two interchangeable biosimilar insulin glargine injection options co-developed with Biocon Biologics will help increase access to critical treatment for millions of Americans living with diabetes
- Oct 13, 2021
- Oct 11, 2021Fortune Recognizes Viatris for Expanding Access to Innovative HIV Medicines, Particularly in Low- and Middle-income Countries
- Aug 30, 2021
- Aug 30, 2021
- Aug 9, 2021Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share
- Jul 28, 2021Interchangeable Designation Allows Substitution at the Pharmacy Counter for Lantus® Across the U.S. to Help Increase Access to Medicines for People Living with Diabetes
- Jul 27, 2021
- Jul 8, 2021
- Jun 23, 2021Company Confident Evidence Regarding Only Remaining Claim Will Show Mylan's Actions Were Lawful and Pro-competitive
- May 25, 2021
- May 10, 2021
- May 6, 2021New company highlights patients, holistic approach to providing access to medicine, and path to further progress
- Apr 30, 2021
- Apr 29, 2021
- Apr 28, 2021
- Apr 12, 2021
- Mar 8, 2021Milestone reinforces Viatris' commitment to complex products and innovative solutions to help increase patient access
- Mar 4, 2021
- Mar 1, 2021
- Feb 22, 2021
- Feb 9, 2021Viatris to host its inaugural virtual Investor Day on March 1, 2021, as previously announced
- Dec 18, 2020
- Dec 15, 2020
- Dec 11, 2020Initiative to Ensure Company is Set Up to Meet its Stated Commitments in Order to Deliver Sustainable Value to Patients, Customers, Shareholders and other Stakeholders
- Dec 10, 2020
- Dec 7, 2020
New animations and materials featuring the Sesame Street Muppets address key emotions that families are feeling during the COVID-19 pandemic - Nov 23, 2020Tentative approval will help enhance access to WHO-recommended pediatric medicine and reduce the cost of HIV treatment for children in low- and middle-income countries
- Nov 16, 2020Combination of Mylan and Pfizer's Upjohn Business Focused on Access and Improved Patient Health
- Nov 2, 2020
- Oct 30, 2020Pfizer Announces Record Date for the Proposed Transaction
- Sep 15, 2020The Companies Have Also Received Approvals in Australia and New Zealand; Combination on Track to Close in Fourth Quarter 2020
- Jul 9, 2020Announcement follows Mylan shareholder approval of Mylan's combination with Pfizer's Upjohn
- Jun 30, 202099.6% of Shares Voted in Favor of the Transaction
- Jun 18, 2020
- Apr 15, 2020
- Mar 26, 2020Due to global impact of COVID-19 pandemic, transaction now expected to close in the second half of 2020 and Mylan's EGM moved to June 30
- Feb 27, 2020Pfizer's Upjohn Division CFO Sanjeev Narula selected for leadership role at combined company
- Feb 27, 202013 Inaugural Directors Bring Wide-Ranging Experience, Expertise and a Focus on Driving Shareholder Value
- Dec 18, 2019Ian Read and James Kilts offer strong experience to support long-term value creation
- Nov 12, 2019
- Jul 29, 2019Delivers enhanced global scale and geographic reach, including leading positions in China and other emerging markets
